Plasmin‐a2‐antiplasmin complexes in bleeding disorders characterized by primary or secondary fibrinolysis

Summary. A two‐dimensional immunoelectrophoresis (2DIEP) method detects plasmin complexed to its major inhibitor, α2‐antiplasmin, in plasma in the blood of patients during (a) thrombolytic therapy with urokinase, (b) episodes of disseminated intravascular coagulation (DIC) with active fibrinolysis, and (c) episodes of fibrinolytic haemorrhage without evidence of DIC. Clearance of the complexes from the blood is rapid and their detection thus implies active plasmin generation at the time of blood sampling or within the preceding 24 h. Abolition of the complexes using tranexamic acid therapy allowed surgery without bleeding in two previously grossly haemorrhagic patients in group (c). Antithrombin III complexed with activated procoagulants was detected using a similar 2DIEP method in only two of fofour patients with DIC. Abnormalities of α2‐macroglobuin were detected on 2DIEP of plasma in the patients studied with proteolytic disorders; these did not appear to reflect complex formation.

[1]  U. Abildgaard,et al.  Gelation of soluble fibrin in plasma by ethanol. , 2009, Scandinavian journal of haematology.

[2]  B. Bennett,et al.  Treatment of venous thrombosis in antithrombin III deficient patients with concentrates of antithrombin III. , 2008, Clinical and laboratory haematology.

[3]  B. Bennett,et al.  A new life-long hemorrhagic disorder due to excess plasminogen activator , 1983 .

[4]  B. Bennett,et al.  PLASMIN‐α2‐ANTIPLASMIN COMPLEX AS AN INDICATOR OF IN VIVO FIBRINOLYSIS , 1982 .

[5]  P. Harpel Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. , 1981, The Journal of clinical investigation.

[6]  B. Bennett,et al.  Comparative Studies on Human Activators of Plasminogen , 1981, British journal of haematology.

[7]  D. Collen On the Regulation and Control of Fibrinolysis , 1980, Thrombosis and Haemostasis.

[8]  E. Plow,et al.  Immunochemical characterization of the plasmin-antiplasmin system. Basis for the specific detection of the plasmin-antiplasmin complex by latex agglutination assays. , 1979, The Journal of laboratory and clinical medicine.

[9]  B. Wiman,et al.  Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. , 1979, Blood.

[10]  M. Verstraete,et al.  Biochemical Changes Noted during Intermittent Administration of Streptokinase , 1978, Thrombosis and Haemostasis.

[11]  M. Matsuda,et al.  The behavior of alpha2-plasmin inhibitor in fibrinolytic states. , 1977, The Journal of clinical investigation.

[12]  D. Collen,et al.  A latex agglutination test for rapid quantitative estimation of the plasmin–antiplasmin complex in human plasma , 1977, European journal of clinical investigation.

[13]  D. Pepper,et al.  Investigations on Antithrombin III in Normal Plasma and Serum , 1975, British journal of haematology.

[14]  I. Nilsson,et al.  Plasmin, plasmin inhibitors, and degradation products of fibrinogen in human serum during and after intravenous infusion of streptokinase. , 1969, Journal of clinical pathology.

[15]  D. Ogston,et al.  Plasma fibrinogen and plasminogen levels in health and in ischaemic heart disease , 1966, Journal of Clinical Pathology.

[16]  O. Ratnoff,et al.  A new method for the determination of fibrinogen in small samples of plasma. , 1951, The Journal of laboratory and clinical medicine.

[17]  P. O. Ganrot,et al.  Plasmin, Plasmin Inhibitors and Degradation Products of Fibrinogen in Human Serum during and after Intravenous Infusion of Streptokinase , 1967 .